Somatostatin receptor 2
Somatostatin receptor 2 is a hormone receptor densely present on neuroendocrine tumours, and was the first theranostic target to reach routine care. This dossier gathers the 7 products (4 approved), 5 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
G-protein-coupled receptor; also expressed in meningioma, small-cell lung cancer, and some breast cancers.
- Neuroendocrine tumours
- Meningioma
- Small-cell lung cancer (subset)
Elsewhere: identifiers and databases
Built from HGNC, Ensembl, UniProt and ChEMBL idsHow common it is, by cancer
Full matrix →| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Neuroendocrine tumours | 80-90% | SSTR PET positivity (well-differentiated) | Lower in grade 3 | Wikipedia |
| Small-cell lung cancer | 30-50% | IHC/imaging | Wikipedia |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Products by modality and phase
Browse products →| Modality | Approved | Phase 3 | Phase 2 |
|---|---|---|---|
| Radiopharmaceutical 5 | |||
| Imaging agent 1 | — | — | |
| Small molecule 1 | — | — |
Trials
Evidence ranking →| Trial | Phase | Status | Setting | Result | Products |
|---|---|---|---|---|---|
| COMPETE NCT03049189 | 3 | Positive | Progressive grade 1-2 SSTR-positive GEP-NETs: 177Lu-edotreotide vs everolimus | PFS 23.9 vs 14.1 months, HR 0.67. | |
| CLARINET NCT00353496 | 3 | Positive | Non-functioning enteropancreatic NETs, grade 1-2: lanreotide 120 mg vs placebo | PFS HR 0.47. | |
| PROMID NCT00171873 | 3 | Positive | Treatment-naive metastatic midgut NETs: octreotide LAR vs placebo | TTP 14.3 vs 6.0 months, HR 0.34. | |
| ACTION-1 NCT05477576 | 3 | Recruiting | SSTR-positive GEP-NETs progressing after 177Lu somatostatin-analogue therapy: 225Ac-DOTATATE (RYZ101) vs investigator's choice | ||
| ALPHAMEDIX-02 NCT05153772 | 2 | Positive | Unresectable or metastatic SSTR-positive GEP-NETs, PRRT-naive and PRRT-exposed cohorts: 212Pb-DOTAMTATE single arm | ORR 54.3% (PRRT-naive); all primary endpoints met. |
Resistance routes that involve this target
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways where it is a node
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics and assays
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Ideas and companies
Key papers and the live literature
Preprints →- NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours · The Lancet 2024
Query for this target: (TITLE:"Somatostatin receptor 2" OR ABSTRACT:"Somatostatin receptor 2" OR TITLE:"SSTR2" OR ABSTRACT:"SSTR2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Somatostatin receptor 2, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/sstr2.json. Licence CC BY 4.0.